[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100378613":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":12,"locations":10,"responsibleParty":22,"collaborators":10,"id":24,"slug":25,"hasResults":26,"nctId":27,"briefTitle":28,"officialTitle":29,"acronym":30,"eligibilityCriteria":31,"healthyVolunteers":26,"sex":32,"minAge":33,"maxAge":10,"enrollmentInfo":34,"targetDuration":10,"studyType":37,"phases":10,"briefSummary":38,"conditions":39,"keywords":10,"overallStatus":41,"whyStopped":10,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":10},{"fullName":5,"class":6},"Assistance Publique - Hôpitaux de Paris","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Patients with haematological malignancy",null,"Patients, aged 15 years or over, with haematological malignancy (Lymphoma, ALL, MM) integrated into a CAR-T Cells program treatment",[13,18],{"name":14,"role":15,"phone":16,"phoneExt":10,"email":17},"Catherine Thieblemont","CONTACT","+331 42 49 92 36","catherine.thieblemont@aphp.fr",{"name":19,"role":15,"phone":20,"phoneExt":20,"email":21},"Matthieu RESCHE-RIGON","0142499742","matthieu.resche-rigon@univ-paris-diderot.fr",{"type":23,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100378613","response-to-chimeric-antigen-receptor-car-t-cells-therapy-in-patients-with-hematologic-malignancies-depending-on-tumor-characteristics-100378613",false,"NCT04209829","Response to Chimeric Antigen Receptor (CAR)-T Cells Therapy in Patients With Hematologic Malignancies Depending on Tumor Characteristics","Response to Chimeric Antigen Receptor (CAR)-T Cells Therapy in Patients With Hematologic Malignancies (Lymphoma, Acute Lymphoblastic Leukemia, Multiple Myeloma) Depending on Tumor Characteristics","BIOCART-HM","Inclusion Criteria:\n\n* patient with hematological malignancy (lymphoma, ALL, MM)\n* patient integrated into a CAR-T Cells program treatment\n* patient aged 15 years or over\n* patient having signed a written consent; as well as his legal representative if \\\u003C18 years old\n\nExclusion Criteria:\n\n* patient with other hematological malignancies than lymphoma, LAL or MM\n* patient's weight \\\u003C58 kg\n* patient treated with another treatment than CAR-T Cells\n* patient under tutorship or curatorship\n* patient not covered by a health system","ALL","15 Years",{"count":35,"type":36},600,"ESTIMATED","OBSERVATIONAL","Immunotherapy with Chimeric Antigen Receptor (CAR) T Cells, T cells whose receptor has been genetically modified, is based on improving the immune response against the tumor. This approach is promising for patients with hematologic malignancies refractory to chemotherapy. Despite impressive results, too many patients are relapsing. The reasons for the relapse, after the injection of CAR T cells, need to be explored. In this context of newly introduced therapeutics, it is essential to better understand the factors associated with the response to treatment with CAR T Cells, especially the characteristics of the tumor and its microenvironment.\n\nThe objective of this study is to understand the role of tumor biology, and its microenvironment, in the response to CAR-T Cells therapy in patients with hematologic malignancies",[40],"Hematologic Diseases","NOT_YET_RECRUITING","2019-12-20",{"date":44,"type":45},"2019-12-24","ACTUAL",{"date":47,"type":36},"2019-12",{"date":49,"type":36},"2035-03",{"name":5,"class":6}]